Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases - Test2 - elhamkhani - TriplyDB

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases

http://www.wikidata.org/entity/Q33883791

about

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis Identification of bacteria from the oral cavity and cloaca of snakes imported from Vietnam.The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae.Strain diversity of CTX-M-producing Enterobacteriaceae in individual pigs: insights into the dynamics of shedding during the production cycle.Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae.Clinical characteristics of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae in the era of CTX-M-type and KPC-type β-lactamases.Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.The continuing challenge of ESBLs.The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms.Clinical significance of extended-spectrum beta-lactamases.International clones of Klebsiella pneumoniae and Escherichia coli with extended-spectrum beta-lactamases in a Czech hospital.VEB-1 extended-spectrum β-lactamase-producing multidrug-resistant Proteus mirabilis sepsis outbreak in a neonatal intensive care unit in India: clinical and diagnostic implications.Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.Characterization and genomic analyses of two newly isolated Morganella phages define distant members among Tevenvirinae and Autographivirinae subfamilies.Genome Sequences of Two Multidrug-Resistant Proteus mirabilis Strains Harboring CTX-M-65 Isolated from Malaysia.Bloodstream infections caused by multi-drug resistant Proteus mirabilis: Epidemiology, risk factors and impact of multi-drug resistance.Pulmonary Pneumatocele in a Pneumonia Patient Infected with Extended-Spectrum β-Lactamase Producing Proteus mirabilis.Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum β-Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae.Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes.Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections.Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae.Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods.Piperacillin-tazobactam as alternative to carbapenems for ICU patients.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Point-Counterpoint: Piperacillin-tazobactam should be used to treat infections with ESBL-positive organisms.β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.Effects of sequential infections of Caenorhabditis elegans with Staphylococcus aureus and Proteus mirabilis.

P2860

Q27002495-E769A57D-A97D-44CE-ADCE-099B74B100DF Q31036673-A29C7C53-CA92-426D-A19F-49EFB880C838 Q33634460-A3724B00-30D8-4AEC-A0A9-EB76E1B40C0D Q34174397-C1E549ED-74D5-4C32-9DCE-5281C2AD2E8C Q34510547-1E7A78EC-66CD-4EC4-BE93-1E3DC9509029 Q34594416-D10F7FAF-0658-40A2-B48C-9F0EE2EA8B25 Q34665473-2F8E5345-F1E1-451E-AC88-A59D5350EAC5 Q35297743-1DC62EC3-715C-4820-913E-56A0CB902591 Q35656192-1454050D-5471-4A8A-A9FC-8A6A7FA08169 Q35715650-D7A3E221-276B-4BBD-A858-F4C7FF547C4D Q35840852-0D4C1DC9-D7DE-41A7-84F3-B2FAD20A1E80 Q36449603-3D33D39B-6E64-4A3C-A625-1781511EF629 Q37208717-F756FD9E-FF66-41F1-B7E5-CFF621EAD124 Q37291354-DA67C048-693F-4521-B865-50DC0A84F811 Q37374794-C09D544F-96FF-4CB1-88E2-81C2BCBBCD7F Q37671577-13EAD73C-EC70-4F8E-A1A5-CC440EDCE1E2 Q37991287-C01CCA47-48B0-4E4E-86C9-AC475E29D6BB Q38165138-F68A5C88-F3D6-467E-B9FD-DF11F015E2E5 Q38497797-80944F4B-F801-4FC2-806D-D4D3B68BF8F4 Q38792841-616FA9A8-2B1B-4283-A092-8CD12A380EF1 Q40260786-0119688E-A65E-413D-985D-6B75EAB89E58 Q40447383-291699D4-98BC-4159-8055-6ECC713CDFD1 Q40834519-8284FD86-59B7-4FF7-81CE-81DF57E1FFD3 Q40934504-14E4AF0E-5018-48A8-A51D-8465FF642836 Q41004466-1D1043A8-1735-465A-9D93-BDB1BFE9DFF3 Q41807595-61345335-7C03-42CA-B36F-70D2D0F13F6E Q41821207-B0FE3B01-AEA0-473E-9554-1B1A86070198 Q41891730-07A3FD51-8023-49B4-BCB7-F411BC464ADF Q41985167-B45B76EF-12F5-452E-9657-62DD7FD5B10B Q43773083-45E174DA-72B7-43A5-A3FD-3FDE0D6D5807 Q44689052-8DB6855A-0BBA-44E5-8F75-1B786902645C Q45711115-09C65551-6212-4622-94A7-E6D78E77BFE1 Q46267269-975F361B-101B-44DA-A81A-14F2C9D3D382 Q47315442-BAFECE26-D9A6-4E0C-A292-D64C9341DABE Q50523195-7710832E-6A04-43E9-8984-D001905B5EB8 Q54293419-BB8C5B4F-AB63-42FA-BE38-7597224D0A1E

P2860

Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases

http://www.wikidata.org/entity/Q33883791

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@ast

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@en

type

label

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@ast

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@en

prefLabel

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@ast

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@en

P1433

Q33883791-56BC0D1C-25E9-4643-8BD3-A88F622A0370

P1476

Q33883791-6B4EF005-54A9-4589-A377-D69C17A84A7E

P2093

Q33883791-0971C475-829E-496D-A1B2-E10AF277B9F2

Q33883791-0E0D0F95-79A3-4784-92D9-49379C3D5F32

Q33883791-11500011-9D42-454C-AEE2-BFEF0C9775B5

Q33883791-3ED1D557-9F3B-4044-A445-EB6DEB178FE0

Q33883791-924C870B-F3F8-4BD2-BA9E-8C3D98879D63

Q33883791-CAC5057C-0E1F-43F5-87F6-B7598F096CE8

Q33883791-DD80B87B-5355-4904-A750-29622F8E4329

Q33883791-F9636FA8-79BD-4610-84B7-D9C3D9F14F29

P2860

Q33883791-0B780261-2357-4F4F-A5F4-CE56B8BF6650

Q33883791-1ACF87EA-0244-4E62-84F8-5B7C7BDA7445

Q33883791-1E5DD1DD-7F26-4E93-866E-5BB12D3BC17E

Q33883791-211D1EE7-5F45-49AD-A7D7-53F25BF85B97

Q33883791-2233C4E7-08B8-4667-8F08-9B1DE64653BE

Q33883791-2D9AAD6A-0F79-4FBB-9287-3E3A0D3A814D

Q33883791-313CFC65-E81F-4C0F-8E1E-09D20E8E2C03

Q33883791-43980615-FF5D-4A71-B07B-E954AA6078F9

Q33883791-45A565C7-579B-4E88-B5C0-CF3C4CF5B9C7

Q33883791-487888A9-A40A-40F7-B6DD-30D24B102590

P304

Q33883791-FC5DA0BC-47E0-4D93-BFAF-9A8526412872

P31

Q33883791-BA26DB9C-CEA2-4B24-AC56-A6D8A969B97E

P356

Q33883791-234EC4F1-3D9D-4095-947A-1D42AC2F2FBC

P407

Q33883791-3DE5304C-C801-4FDD-84B1-FCB657CDFA33

P433

Q33883791-39965661-E4AE-40F9-A04B-F80029CF1E49

P478

Q33883791-A4AC5EE5-A001-4FB8-9F9B-E5E8FEDFB41E

P577

Q33883791-5B3E6EDE-5E8F-49BF-A6C7-794957001EE5

P5875

Q33883791-37CA6A97-1AD2-4446-8F7A-B2D9BAE32C75

P698

Q33883791-88512429-413F-43E9-B0B8-5F4162772AFF

P932

Q33883791-7C540A53-3E7F-4F0A-B9C4-90C81F10CDD8

P356

AAC.49.7.2598-2605.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Proteus mirabilis bloodstream ...... ended-spectrum beta-lactamases

@en

P2093

Andrea Endimiani

http://www.w3.org/2001/XMLSchema#string

Antonio Toniolo

http://www.w3.org/2001/XMLSchema#string

Francesco Luzzaro

http://www.w3.org/2001/XMLSchema#string

Gian Maria Rossolini

http://www.w3.org/2001/XMLSchema#string

Gianfranco Amicosante

http://www.w3.org/2001/XMLSchema#string

Gianluigi Lombardi

http://www.w3.org/2001/XMLSchema#string

Gioconda Brigante

http://www.w3.org/2001/XMLSchema#string

Mariagrazia Perilli

http://www.w3.org/2001/XMLSchema#string

P2860

Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat

Classification, identification, and clinical significance of Proteus, Providencia, and Morganella

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.

Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group.

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs

Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome

Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs).

Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals.

P304

2598-2605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.49.7.2598-2605.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7764135

http://www.w3.org/2001/XMLSchema#string

P698

15980325

http://www.w3.org/2001/XMLSchema#string

P932

1168714

http://www.w3.org/2001/XMLSchema#string